Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

56.31 -0.50 (-0.88%)
Streaming Delayed Price Updated: 10:05 AM EDT, Jul 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 191,512
Open 57.35
Bid (Size) 56.30 (300)
Ask (Size) 56.38 (300)
Prev. Close 56.81
Today's Range 56.04 - 57.35
52wk Range 14.36 - 60.10
Shares Outstanding 60,717,176
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗
Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s.... 
Via InvestorPlace
News headline image
Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
From Travere Therapeutics, Inc.
Via Business Wire

Performance

YTD
+42.5%
+42.5%
1 Month
+25.0%
+25.0%
3 Month
+89.5%
+89.5%
6 Month
+49.4%
+49.4%
1 Year
+280.5%
+280.5%

More News

Read More
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics (NASDAQ:TVTX) Q1 2026 Results Show Record FILSPARI Sales and FSGS Approval, but Revenue and EPS Miss Estimates ↗
Via Chartmill
News headline image
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Validating headline phrasing and editorial resonance A Director Cashes In Near the Top, but What Remains Matters ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Travere Therapeutics to Participate at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings ↗
Via Benzinga
News headline image
Travere (TVTX) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Travere Therapeutics Reports First Quarter 2026 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere (TVTX) Q2 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Travere (TVTX) Q4 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Travere Therapeutics to Report First Quarter 2026 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Director Trims Stake Amid 168% Run, But Is FILSPARI's Revenue Story Just Getting Started? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
These stocks are moving in today's session ↗
Via Chartmill
Topics Artificial Intelligence
News headline image
Tuesday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Biogen's $5.6 Billion Acquisition of Apellis: A Strategic Pivot into Rare Kidney Diseases
Via MarketMinute

Frequently Asked Questions

Is Travere Therapeutics, Inc. - Common Stock publicly traded?
Yes, Travere Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Travere Therapeutics, Inc. - Common Stock trade on?
Travere Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Travere Therapeutics, Inc. - Common Stock?
The ticker symbol for Travere Therapeutics, Inc. - Common Stock is TVTX on the Nasdaq Stock Market
What is the current price of Travere Therapeutics, Inc. - Common Stock?
The current price of Travere Therapeutics, Inc. - Common Stock is 56.31
When was Travere Therapeutics, Inc. - Common Stock last traded?
The last trade of Travere Therapeutics, Inc. - Common Stock was at 07/01/26 10:05 AM ET
What is the market capitalization of Travere Therapeutics, Inc. - Common Stock?
The market capitalization of Travere Therapeutics, Inc. - Common Stock is 3.42B
How many shares of Travere Therapeutics, Inc. - Common Stock are outstanding?
Travere Therapeutics, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.